Skip to main content

The ghost of personalized medicine

Drug therapies tailored to the DNA profiles of individual patients could change the face of medicine, but such treatments aren't commonly used in the clinic.

Written byBob Grant
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00

"Doctor's Visit" (detail)JAN STEEN

The US Food and Drug Administration recommends that doctors genotype patients before prescribing more than 70 commonly-used medications for specific genetic biomarkers. These tests, the agency suggests, can help physicians identify those in which the drug is less efficacious, poorly metabolized, or dangerous. But medicine is still far from a day when drugs and treatment regimes are fitted precisely to a patient's genomic profile.

According to a 2008 survey conducted by the American Medical Association (AMA) and Medco Research Institute, even though 98 percent of physicians agreed that the genetic profiles of their patients may influence drug therapy, only 10 percent believed they were adequately informed about how to test their patients for biomarkers that may predict the safety and/or efficacy of a particular drug.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Related Topics

The Scientist October Digest cover
October 2026

Antarctica’s Blood Falls Teems With Mysterious Microbial Life

Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.

View this Issue
Evaluating Blood Biomarkers for Alzheimer’s Disease Staging

Evaluating Blood Biomarkers for Alzheimer’s Disease Staging

​Beckman Coulter
Find better biologics faster with Stunner and the AI Developability Workcell

Find better biologics faster with Stunner and the AI Developability Workcell

Unchained Labs
An image of microcentrifuge tubes arranged within colorful laboratory racks.

Choose clarity. Choose speed. Choose MyMass™

Refeyn
Characterizing LNP Heterogeneity With Super-Resolution Imaging

Characterizing LNP Heterogeneity With Super-Resolution Imaging

Oni

Products

Stellaromics Logo

Stellaromics Expands Pyxa Adoption as Instruments are Installed at Leading Research Institutions Across the U.S. and EuropeStellaromics, Inc., the leader in 3D

A monoclonal antibody surrounded by immune cells and red blood cells

CellRaft AIR: Find the Right Antibody-Producing Cells Faster

Cell Microsystems
Maxwell® Rapid ccfDNA Kit

Maxwell® Rapid ccfDNA Kit: Automated Purification of ccfDNA in Under 30 Minutes

Promega
Leica Biosystems, Tempus, and Paige logos side by side, marking the addition of Paige digital pathology AI tools to the Aperio AI Store.

Oncology Researchers Gain AI Cancer Tools in One Platform